Literature DB >> 11468742

A case of human orf in an immunocompromised patient treated successfully with cidofovir cream.

K Geerinck1, G Lukito, R Snoeck, R De Vos, E De Clercq, Y Vanrenterghem, H Degreef, B Maes.   

Abstract

Immunocompromised patients may have severe forms of infections. Since there is an increasing number of patients maintained under immunosuppressive therapy, we will be confronted with increasing frequency with these infectious problems. Effective treatments will be of great value. The case is described of a renal transplant with a giant orf lesion, which continued growing instead of regressing spontaneously as is observed usually. The treatment options in such patients are limited. It was decided to treat the patient with the antiviral drug cidofovir (HPMPC, Vistide. Topical cidofovir treatment resulted in complete regression of the lesion. This case is discussed in the context of the known literature on orf (ecthyma contagiosum). Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11468742     DOI: 10.1002/jmv.1084

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  30 in total

1.  Orf Infection in a Patient with Stat1 Gain-of-Function.

Authors:  Sara Sebnem Kilic; Anne Puel; Jean-Laurent Casanova
Journal:  J Clin Immunol       Date:  2014-11-04       Impact factor: 8.317

2.  Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice.

Authors:  Graciela Andrei; Don B Gammon; Pierre Fiten; Erik De Clercq; Ghislain Opdenakker; Robert Snoeck; David H Evans
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

3.  Activities of acyclic nucleoside phosphonates against Orf virus in human and ovine cell monolayers and organotypic ovine raft cultures.

Authors:  F Dal Pozzo; G Andrei; A Holy; J Van Den Oord; A Scagliarini; E De Clercq; R Snoeck
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

4.  Antiviral activity of HPMPC (cidofovir) against orf virus infected lambs.

Authors:  A Scagliarini; C J McInnes; L Gallina; F Dal Pozzo; L Scagliarini; R Snoeck; S Prosperi; J Sales; J A Gilray; P F Nettleton
Journal:  Antiviral Res       Date:  2006-10-11       Impact factor: 5.970

5.  Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate.

Authors:  Wendy C Magee; Karl Y Hostetler; David H Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

6.  Milker's nodules: classic histological findings.

Authors:  Ana Cláudia Cavalcante Espósito; Marilia Formentini Scotton Jorge; Mariângela Esther Alencar Marques; Luciana Patrícia Fernandes Abbade
Journal:  An Bras Dermatol       Date:  2017 Nov-Dec       Impact factor: 1.896

Review 7.  Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Authors:  Kathleen E Sullivan; Hamid Bassiri; Ahmed A Bousfiha; Beatriz T Costa-Carvalho; Alexandra F Freeman; David Hagin; Yu L Lau; Michail S Lionakis; Ileana Moreira; Jorge A Pinto; M Isabel de Moraes-Pinto; Amit Rawat; Shereen M Reda; Saul Oswaldo Lugo Reyes; Mikko Seppänen; Mimi L K Tang
Journal:  J Clin Immunol       Date:  2017-08-07       Impact factor: 8.317

Review 8.  Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.

Authors:  Erik De Clercq
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

9.  Therapeutic paint of cidofovir/sucralfate gel combination topically administered by spraying for treatment of orf virus infections.

Authors:  Fabio Sonvico; Gaia Colombo; Laura Gallina; Fabrizio Bortolotti; Alessandra Rossi; Colin J McInnes; Gina Massimo; Paolo Colombo; Alessandra Scagliarini
Journal:  AAPS J       Date:  2009-04-21       Impact factor: 4.009

10.  Activities of several classes of acyclic nucleoside phosphonates against camelpox virus replication in different cell culture models.

Authors:  Sophie Duraffour; Robert Snoeck; Marcela Krecmerová; Joost van Den Oord; Rita De Vos; Antonín Holy; Jean-Marc Crance; Daniel Garin; Erik De Clercq; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2007-09-24       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.